Oncology Pharma Reveals Strategic Plans for Company Growth and Focus

March 16, 2021 8:00 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWireOncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property and business model. Key focal points include expansion of its cancer therapeutics through acquisition of license agreements and formation of synergistic partnerships and expansion of other niche therapeutics. Also, an important part of the Company’s strategic plans include the goal of forming financial partnerships that allow the development of licensed therapeutic agents.   

Oncology Pharma’s spokesperson has stated, “We are looking to expand our products under development in a way that they dovetail together and define our brand. Currently, we have identified potential financing sources for short term and midterm financings.”

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

FORWARD-LOOKING STATEMENTS

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

CONTACTS:For additional information, please contact the Oncology Pharma at:One Sansome Street, Suite 3500San Francisco, CA 94104Phone: 415-869-1038 Fax: 415-946-8801 Website: www.oncology-pharma.comEmail: info@oncology-pharma.com

Source: Oncology Pharma, Inc.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Globe Newswire, Press Releases

Related Entities

Definitive Agreement